X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

By Jocelyn Ulrich  |    September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    September 8, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    August 24, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

By Tom Wilbur  |    July 22, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

By Jocelyn Ulrich  |    July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

By Tom Wilbur  |    July 2, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

By Tom Wilbur  |    June 5, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new treatments and cures for patients. Strong IP protections are...   Read More

IP Explained: Intellectual property system working to combat COVID-19

By Megan Van Etten  |    May 28, 2020
Biopharmaceutical companies are working around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among...   Read More

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19

By Tom Wilbur  |    May 4, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP...   Read More

The continued imperative to protect U.S. innovation worldwide

By Chris Moore  |    April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates